Abstract

Currently, there is no effective way to assess the therapeutic response of temozolomide (TMZ) for the glioma. In this study, the human U87MG-fLuc glioma animal models were set up and the antitumor efficacy of TMZ was evaluated using bioluminescence imaging (BLI) and MRI. Then, bioluminescence tomography (BLT) was reconstructed using an adaptive sparsity matching pursuit (ASMP) algorithm. Second, the expression level of the MMP-750 probe was examined with or without TMZ treatment using FMI. Third, the expression of MMP2 and MMP3 was specifically examined after treatment. The results showed that TMZ effectively inhibited glioma growth. The targeted imaging of MMP-750 was decreased during the treatment of glioma with TMZ. Moreover, the MMP2 and MMP3 expression was found to correlate with the inhibition effect of TMZ. Our study indicated that the therapeutic effects of TMZ can be effectively evaluated at an early stage using molecular imaging, and MMP targeting the fluorescence probe could be utilized for the prediction and assessment of the therapeutic effects of TMZ.

© 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement

Full Article  |  PDF Article
OSA Recommended Articles
Early detection of liver cancer based on bioluminescence tomography

Xibo Ma, Jie Tian, Chenghu Qin, Xin Yang, Bo Zhang, Zhenwen Xue, Xing Zhang, Dong Han, Di Dong, and Xueyan Liu
Appl. Opt. 50(10) 1389-1395 (2011)

Intravital imaging of mouse colonic adenoma using MMP-based molecular probes with multi-channel fluorescence endoscopy

Gyungseok Oh, Su Woong Yoo, Yebin Jung, Yeon-Mi Ryu, Youngrong Park, Sang-Yeob Kim, Ki Hean Kim, Sungjee Kim, Seung-Jae Myung, and Euiheon Chung
Biomed. Opt. Express 5(5) 1677-1689 (2014)

Non-invasive dual fluorescence in vivo imaging for detection of macrophage infiltration and matrix metalloproteinase (MMP) activity in inflammatory arthritic joints

Hongsik Cho, Fazal-Ur-Rehman Bhatti, Tae Won Yoon, Karen A. Hasty, John M. Stuart, and Ae-Kyung Yi
Biomed. Opt. Express 7(5) 1842-1852 (2016)

References

  • View by:
  • |
  • |
  • |

  1. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
    [Crossref] [PubMed]
  2. E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
    [Crossref] [PubMed]
  3. P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
    [Crossref] [PubMed]
  4. E. Galanis and J. Buckner, “Chemotherapy for high-grade gliomas,” Br. J. Cancer 82(8), 1371–1380 (2000).
    [Crossref] [PubMed]
  5. M. Brada, and M. Prados (ed). Brain Cancer,” Ann Oncol 13, 1511 (2002).
  6. T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
    [Crossref] [PubMed]
  7. H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
    [Crossref] [PubMed]
  8. M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
    [Crossref] [PubMed]
  9. M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
    [Crossref] [PubMed]
  10. M. F. Stevens, J. A. Hickman, S. P. Langdon, D. Chubb, L. Vickers, R. Stone, G. Baig, C. Goddard, N. W. Gibson, and J. A. Slack, Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine (William B. Eerdmans, 1987), pp. 5846–5852.
  11. W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
    [Crossref] [PubMed]
  12. W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
    [Crossref] [PubMed]
  13. C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annu. Rev. Biomed. Eng. 4(1), 235–260 (2002).
    [Crossref] [PubMed]
  14. A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
    [Crossref] [PubMed]
  15. V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
    [Crossref] [PubMed]
  16. A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
    [Crossref] [PubMed]
  17. A. Söling and N. G. Rainov, “Bioluminescence imaging in vivo - application to cancer research,” Expert Opin. Biol. Ther. 3(7), 1163–1172 (2003).
    [PubMed]
  18. J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
    [Crossref] [PubMed]
  19. G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).
  20. G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
    [Crossref] [PubMed]
  21. C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
    [Crossref] [PubMed]
  22. M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nat. Rev. Cancer 2(3), 161–174 (2002).
    [Crossref] [PubMed]
  23. A. F. Chambers and L. M. Matrisian, “Changing Views of the Role of Matrix Metalloproteinases in Metastasis,” J. Natl. Cancer Inst. 89(17), 1260–1270 (1997).
    [Crossref] [PubMed]
  24. L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they’re not just for matrix anymore!” Curr. Opin. Cell Biol. 13(5), 534–540 (2001).
    [Crossref] [PubMed]
  25. M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
    [Crossref] [PubMed]
  26. M. E. Stearns and M. Wang, “Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue,” Cancer Res. 53(4), 878–883 (1993).
    [PubMed]
  27. B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
    [PubMed]
  28. S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
    [Crossref] [PubMed]
  29. M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
    [PubMed]
  30. J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
    [Crossref] [PubMed]
  31. A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
    [Crossref] [PubMed]
  32. Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
    [Crossref] [PubMed]
  33. P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
    [Crossref] [PubMed]
  34. I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
    [Crossref] [PubMed]
  35. H. Wu and S. Wang, “Adaptive Sparsity Matching Pursuit Algorithm for Sparse Reconstruction,” IEEE Signal Process. Lett. 19(8), 471–474 (2012).
    [Crossref]
  36. H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
    [PubMed]
  37. J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
    [Crossref] [PubMed]
  38. M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
    [Crossref] [PubMed]
  39. M. Folaron and M. Seshadri, “Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas,” Mol. Imaging Biol. 18(6), 860–869 (2016).
    [Crossref] [PubMed]
  40. C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
    [Crossref] [PubMed]
  41. T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70(2), 217–228 (2004).
    [Crossref] [PubMed]
  42. J. Gross and C. M. Lapiere, “Collagenolytic activity in amphibian tissues: a tissue culture assay,” Proc. Natl. Acad. Sci. U.S.A. 48(6), 1014–1022 (1962).
    [Crossref] [PubMed]
  43. S. Curran and G. I. Murray, “Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis,” Eur. J. Cancer 36(13), 1621–1630 (2000).
    [Crossref] [PubMed]
  44. L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
    [Crossref] [PubMed]
  45. H. Nagase and J. F. Woessner., “Matrix metalloproteinases,” J. Biol. Chem. 274(31), 21491–21494 (1999).
    [Crossref] [PubMed]
  46. A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
    [Crossref] [PubMed]
  47. B. Shrestha and S. Subedi, “Matrix Metalloproteinase,” Curr Opin 84, 160 (1997).

2016 (2)

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

M. Folaron and M. Seshadri, “Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas,” Mol. Imaging Biol. 18(6), 860–869 (2016).
[Crossref] [PubMed]

2013 (2)

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

2012 (2)

H. Wu and S. Wang, “Adaptive Sparsity Matching Pursuit Algorithm for Sparse Reconstruction,” IEEE Signal Process. Lett. 19(8), 471–474 (2012).
[Crossref]

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

2011 (1)

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

2010 (2)

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

2006 (1)

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

2005 (3)

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

2004 (3)

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
[Crossref] [PubMed]

T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70(2), 217–228 (2004).
[Crossref] [PubMed]

2003 (5)

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

A. Söling and N. G. Rainov, “Bioluminescence imaging in vivo - application to cancer research,” Expert Opin. Biol. Ther. 3(7), 1163–1172 (2003).
[PubMed]

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
[Crossref] [PubMed]

2002 (2)

M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nat. Rev. Cancer 2(3), 161–174 (2002).
[Crossref] [PubMed]

C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annu. Rev. Biomed. Eng. 4(1), 235–260 (2002).
[Crossref] [PubMed]

2001 (3)

C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
[Crossref] [PubMed]

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they’re not just for matrix anymore!” Curr. Opin. Cell Biol. 13(5), 534–540 (2001).
[Crossref] [PubMed]

2000 (6)

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

E. Galanis and J. Buckner, “Chemotherapy for high-grade gliomas,” Br. J. Cancer 82(8), 1371–1380 (2000).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

S. Curran and G. I. Murray, “Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis,” Eur. J. Cancer 36(13), 1621–1630 (2000).
[Crossref] [PubMed]

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

1999 (4)

H. Nagase and J. F. Woessner., “Matrix metalloproteinases,” J. Biol. Chem. 274(31), 21491–21494 (1999).
[Crossref] [PubMed]

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

1998 (2)

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
[Crossref] [PubMed]

1997 (2)

A. F. Chambers and L. M. Matrisian, “Changing Views of the Role of Matrix Metalloproteinases in Metastasis,” J. Natl. Cancer Inst. 89(17), 1260–1270 (1997).
[Crossref] [PubMed]

B. Shrestha and S. Subedi, “Matrix Metalloproteinase,” Curr Opin 84, 160 (1997).

1993 (3)

M. E. Stearns and M. Wang, “Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue,” Cancer Res. 53(4), 878–883 (1993).
[PubMed]

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
[Crossref] [PubMed]

1980 (1)

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

1962 (1)

J. Gross and C. M. Lapiere, “Collagenolytic activity in amphibian tissues: a tissue culture assay,” Proc. Natl. Acad. Sci. U.S.A. 48(6), 1014–1022 (1962).
[Crossref] [PubMed]

Abel, P.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Albright, R.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Albright, R. E.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Allgeier, A.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Auffinger, B.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Bachmann, M. H.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annu. Rev. Biomed. Eng. 4(1), 235–260 (2002).
[Crossref] [PubMed]

Balkwill, F.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Baryshnikov, A. Y.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Batra, V.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Beale, P.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Belanger, K.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Berens, M. E.

T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70(2), 217–228 (2004).
[Crossref] [PubMed]

Bogdahn, U.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Borovjagin, A.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Boyd, D.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Brada, M.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Bradley, M. K.

P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
[Crossref] [PubMed]

Brandes, A. A.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Bravo-Marques, J. M.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Bremer, C.

C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
[Crossref] [PubMed]

Brock, M.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Bruner, J.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Buckner, J.

E. Galanis and J. Buckner, “Chemotherapy for high-grade gliomas,” Br. J. Cancer 82(8), 1371–1380 (2000).
[Crossref] [PubMed]

Butterfield, C.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Cai, J.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Cairncross, J. G.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Cao, F.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Cao, Y. A.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

Cardozo, S. J.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Carette, J. E.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Chambers, A. F.

A. F. Chambers and L. M. Matrisian, “Changing Views of the Role of Matrix Metalloproteinases in Metastasis,” J. Natl. Cancer Inst. 89(17), 1260–1270 (1997).
[Crossref] [PubMed]

Chang, S. M.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Chen, B.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Chen, I. Y.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Chiocca, E. A.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Cong, W.

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

Conner, C.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Contag, C. H.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
[Crossref] [PubMed]

C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annu. Rev. Biomed. Eng. 4(1), 235–260 (2002).
[Crossref] [PubMed]

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Curran, S.

S. Curran and G. I. Murray, “Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis,” Eur. J. Cancer 36(13), 1621–1630 (2000).
[Crossref] [PubMed]

Curschmann, J.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Cutler, D.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Davies, B.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

De, A.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Demuth, T.

T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70(2), 217–228 (2004).
[Crossref] [PubMed]

Dey, M.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Dietrich, P. Y.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Dirix, L. Y.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Dirven, C. M.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Dugan, M.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Edinger, M.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

Egeblad, M.

M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nat. Rev. Cancer 2(3), 161–174 (2002).
[Crossref] [PubMed]

Eisenhauer, E.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Fang, J.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Feng, Y.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Fidler, I. J.

J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
[Crossref] [PubMed]

Fingleton, B.

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

Fink, K.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Fishbein, M. C.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Fisher, B.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Folaron, M.

M. Folaron and M. Seshadri, “Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas,” Mol. Imaging Biol. 18(6), 860–869 (2016).
[Crossref] [PubMed]

Foltz, C. M.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Fredericks, R.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Freeman, M. R.

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Friedman, A. H.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Friedman, H.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Friedman, H. S.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Galanis, E.

E. Galanis and J. Buckner, “Chemotherapy for high-grade gliomas,” Br. J. Cancer 82(8), 1371–1380 (2000).
[Crossref] [PubMed]

Galiger, C.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Gambhir, S. S.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Garbisa, S.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Germano, I. M.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Gerritsen, W. R.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Gianni, D.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Glantz, M.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Gorlia, T.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Greenberg, H.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Greuber, E. K.

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

Gross, J.

J. Gross and C. M. Lapiere, “Collagenolytic activity in amphibian tissues: a tissue culture assay,” Proc. Natl. Acad. Sci. U.S.A. 48(6), 1014–1022 (1962).
[Crossref] [PubMed]

Guo, D.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Gupta, S.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Hadjipanayis, C. G.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Hall, D. E.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Han, B.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Han, W.

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

Han, Y.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Hanby, A.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Harper, J.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Hart, I.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Heimans, J. J.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Henriksson, R.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Hibner, U.

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Hoang-Xuan, K.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Hohl, R. J.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Hu, H.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Hurewitz, A. N.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Hymowitz, M.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Ibrahim-Granet, O.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Idema, S.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Ito, H.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Jackson, G.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Janzer, R. C.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Jiang, C.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Jiang, M.

G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
[Crossref] [PubMed]

Jouvion, G.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Judson, I.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Kaminska, B.

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Kanzawa, T.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Kay, M. A.

A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
[Crossref] [PubMed]

Kijewska, M.

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Killion, J. J.

J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
[Crossref] [PubMed]

Kim, C. K.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Komata, T.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Kondo, S.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Kondo, Y.

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Kornblith, P. K.

P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
[Crossref] [PubMed]

Krausz, T.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Kurzen, H.

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

Kwiatkowska, A.

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Lacombe, D.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Lamb, C. C.

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Lamfers, M. L.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Lapiere, C. M.

J. Gross and C. M. Lapiere, “Collagenolytic activity in amphibian tissues: a tissue culture assay,” Proc. Natl. Acad. Sci. U.S.A. 48(6), 1014–1022 (1962).
[Crossref] [PubMed]

Lesniak, M. S.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Levin, V. A.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Li, J.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Li, Q.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Li, R.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Li, Y.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
[Crossref] [PubMed]

Liang, J.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Liotta, L. A.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Lipko, M.

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Liu, J.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Liu, X.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Loughlin, K. R.

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Ludwin, S. K.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Macdonald, D.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Marosi, C.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Mason, W. P.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Matrisian, L.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Matrisian, L. M.

L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they’re not just for matrix anymore!” Curr. Opin. Cell Biol. 13(5), 534–540 (2001).
[Crossref] [PubMed]

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

A. F. Chambers and L. M. Matrisian, “Changing Views of the Role of Matrix Metalloproteinases in Metastasis,” J. Natl. Cancer Inst. 89(17), 1260–1270 (1997).
[Crossref] [PubMed]

McCaffrey, A.

A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
[Crossref] [PubMed]

McCawley, L. J.

L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they’re not just for matrix anymore!” Curr. Opin. Cell Biol. 13(5), 534–540 (2001).
[Crossref] [PubMed]

Min, J. J.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Mirimanoff, R. O.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Möhler, T.

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

Montana, S.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Moore, S.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Moses, M. A.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Murray, G. I.

S. Curran and G. I. Murray, “Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis,” Eur. J. Cancer 36(13), 1621–1630 (2000).
[Crossref] [PubMed]

Nagase, H.

H. Nagase and J. F. Woessner., “Matrix metalloproteinases,” J. Biol. Chem. 274(31), 21491–21494 (1999).
[Crossref] [PubMed]

Näher, H.

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

Neal, D.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Negrin, R. S.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

Nelson, A. R.

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

Nicolson, G.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Nie, Y.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Norden, A. D.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Ntziachristos, V.

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

O’Neill, A. M.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Olson, J.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Olson, J. J.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Osoba, D.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Parlato, M.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Pendergast, A. M.

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

Phillips, P.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Prados, M. D.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Pytel, P.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Qiao, J. H.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Quax, P. H.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Radinsky, R.

J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
[Crossref] [PubMed]

Rainov, N. G.

A. Söling and N. G. Rainov, “Bioluminescence imaging in vivo - application to cancer research,” Expert Opin. Biol. Ther. 3(7), 1163–1172 (2003).
[PubMed]

Rampling, R.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Rao, S.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Rehemtulla, A.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Reidenberg, P.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Ripoll, J.

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

Rosenfeld, S. S.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Ross, B. D.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Rothenberg, M. L.

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

Sarvaiya, P.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Savers, A.

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Schagen, F. H.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Schmitt, S.

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

Selker, R. G.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Seshadri, M.

M. Folaron and M. Seshadri, “Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas,” Mol. Imaging Biol. 18(6), 860–869 (2016).
[Crossref] [PubMed]

Shafie, S.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Shapiro, W.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Shing, Y.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Shrestha, B.

B. Shrestha and S. Subedi, “Matrix Metalloproteinase,” Curr Opin 84, 160 (1997).

Shu, H. K.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Smith-Pearson, P. S.

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

Söling, A.

A. Söling and N. G. Rainov, “Bioluminescence imaging in vivo - application to cancer research,” Expert Opin. Biol. Ther. 3(7), 1163–1172 (2003).
[PubMed]

Spence, A.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Statkevich, P.

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

Stearns, M. E.

M. E. Stearns and M. Wang, “Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue,” Cancer Res. 53(4), 878–883 (1993).
[PubMed]

Stegman, L. D.

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Stupp, R.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Su, N.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Subedi, S.

B. Shrestha and S. Subedi, “Matrix Metalloproteinase,” Curr Opin 84, 160 (1997).

Sun, Y.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Sundaresan, G.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Tamvakopoulos, G.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Taphoorn, M. J.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Thaci, B.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Thomas, D.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Tian, Y.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Tryggvason, K.

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Tung, C. H.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
[Crossref] [PubMed]

Ulasov, I.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Van Beusechem, V. W.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

van den Bent, M. J.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Van Meir, E. G.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Vandertop, W. P.

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

Verneris, M. R.

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

Vick, N. A.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Wang, G.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
[Crossref] [PubMed]

Wang, L. V.

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

Wang, M.

M. E. Stearns and M. Wang, “Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue,” Cancer Res. 53(4), 878–883 (1993).
[PubMed]

Wang, S.

H. Wu and S. Wang, “Adaptive Sparsity Matching Pursuit Algorithm for Sparse Reconstruction,” IEEE Signal Process. Lett. 19(8), 471–474 (2012).
[Crossref]

Wasan, H.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Waxman, J.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Weissleder, R.

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
[Crossref] [PubMed]

Welch, W. C.

P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
[Crossref] [PubMed]

Weller, M.

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Wen, P. Y.

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Werb, Z.

M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nat. Rev. Cancer 2(3), 161–174 (2002).
[Crossref] [PubMed]

Wiederschain, D.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Williams, G.

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Woessner, J. F.

H. Nagase and J. F. Woessner., “Matrix metalloproteinases,” J. Biol. Chem. 274(31), 21491–21494 (1999).
[Crossref] [PubMed]

Wu, H.

H. Wu and S. Wang, “Adaptive Sparsity Matching Pursuit Algorithm for Sparse Reconstruction,” IEEE Signal Process. Lett. 19(8), 471–474 (2012).
[Crossref]

Wu, J. C.

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Wu, K.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Yan, L.

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

Yao, L.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Yaya-Tur, R.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Yi, L.

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Yi, R.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Yin, J.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

Yogalingam, G.

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

Yue, N.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Yung, W. K.

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Yung, W. K. A.

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

Zaknoen, S.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

Zarrabi, H. M.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Zhang, L.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Zonnenberg, B. A.

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Zucker, S.

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Zurakowski, D.

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

Ann. N. Y. Acad. Sci. (1)

S. Zucker, M. Hymowitz, C. Conner, H. M. Zarrabi, A. N. Hurewitz, L. Matrisian, D. Boyd, G. Nicolson, and S. Montana, “Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues. Clinical and Experimental Applications,” Ann. N. Y. Acad. Sci. 878(1 INHIBITION OF), 212–227 (1999).
[Crossref] [PubMed]

Ann. Oncol. (1)

M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao, and S. Zaknoen, “Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse,” Ann. Oncol. 12(2), 259–266 (2001).
[Crossref] [PubMed]

Annu. Rev. Biomed. Eng. (1)

C. H. Contag and M. H. Bachmann, “Advances in in vivo bioluminescence imaging of gene expression,” Annu. Rev. Biomed. Eng. 4(1), 235–260 (2002).
[Crossref] [PubMed]

Anticancer Drugs (1)

H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anticancer Drugs 14(7), 515–522 (2003).
[Crossref] [PubMed]

Antimicrob. Agents Chemother. (1)

C. Galiger, M. Brock, G. Jouvion, A. Savers, M. Parlato, and O. Ibrahim-Granet, “Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging,” Antimicrob. Agents Chemother. 57(7), 3046–3059 (2013).
[Crossref] [PubMed]

Biochim. Biophys. Acta (1)

A. Kwiatkowska, M. Kijewska, M. Lipko, U. Hibner, and B. Kaminska, “Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression,” Biochim. Biophys. Acta 1813(5), 655–667 (2011).
[Crossref] [PubMed]

Blood (1)

M. Edinger, Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood 101(2), 640–648 (2003).
[Crossref] [PubMed]

Br. J. Cancer (3)

W. K. A. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, and V. A. Levin, “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse,” Br. J. Cancer 83(5), 588–593 (2000).
[Crossref] [PubMed]

M. Brada, I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, M. Dugan, V. Batra, and D. Cutler, “Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,” Br. J. Cancer 81(6), 1022–1030 (1999).
[Crossref] [PubMed]

E. Galanis and J. Buckner, “Chemotherapy for high-grade gliomas,” Br. J. Cancer 82(8), 1371–1380 (2000).
[Crossref] [PubMed]

CA Cancer J. Clin. (1)

E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: the avenue to a cure for malignant glioma,” CA Cancer J. Clin. 60(3), 166–193 (2010).
[Crossref] [PubMed]

Cancer Med. (1)

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo, B. Auffinger, P. Pytel, L. Zhang, C. K. Kim, A. Borovjagin, M. Dey, Y. Han, A. Y. Baryshnikov, and M. S. Lesniak, “Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas,” Cancer Med. 2(4), 457–467 (2013).
[Crossref] [PubMed]

Cancer Metastasis Rev. (1)

J. J. Killion, R. Radinsky, and I. J. Fidler, “Orthotopic models are necessary to predict therapy of transplantable tumors in mice,” Cancer Metastasis Rev. 17(3), 279–284 (1998).
[Crossref] [PubMed]

Cancer Res. (4)

M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Res. 58(7), 1395–1399 (1998).
[PubMed]

M. L. Lamfers, D. Gianni, C. H. Tung, S. Idema, F. H. Schagen, J. E. Carette, P. H. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M. Dirven, E. A. Chiocca, and W. R. Gerritsen, “Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma,” Cancer Res. 65(20), 9398–9405 (2005).
[Crossref] [PubMed]

M. E. Stearns and M. Wang, “Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue,” Cancer Res. 53(4), 878–883 (1993).
[PubMed]

B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby, and F. Balkwill, “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion,” Cancer Res. 53(22), 5365–5369 (1993).
[PubMed]

Cell Death Differ. (1)

T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death Differ. 11(4), 448–457 (2004).
[Crossref] [PubMed]

Circulation (1)

J. C. Wu, I. Y. Chen, G. Sundaresan, J. J. Min, A. De, J. H. Qiao, M. C. Fishbein, and S. S. Gambhir, “Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography,” Circulation 108(11), 1302–1305 (2003).
[Crossref] [PubMed]

Curr Opin (1)

B. Shrestha and S. Subedi, “Matrix Metalloproteinase,” Curr Opin 84, 160 (1997).

Curr. Opin. Cell Biol. (1)

L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they’re not just for matrix anymore!” Curr. Opin. Cell Biol. 13(5), 534–540 (2001).
[Crossref] [PubMed]

Eur. J. Cancer (1)

S. Curran and G. I. Murray, “Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis,” Eur. J. Cancer 36(13), 1621–1630 (2000).
[Crossref] [PubMed]

Expert Opin. Biol. Ther. (1)

A. Söling and N. G. Rainov, “Bioluminescence imaging in vivo - application to cancer research,” Expert Opin. Biol. Ther. 3(7), 1163–1172 (2003).
[PubMed]

IEEE Int Symp Biomed Imaging (1)

G. Wang, W. Cong, Y. Li, and W. Han, “Recent development in bioluminescence tomography,” IEEE Int Symp Biomed Imaging 2, 678–681 (2006).

IEEE Signal Process. Lett. (1)

H. Wu and S. Wang, “Adaptive Sparsity Matching Pursuit Algorithm for Sparse Reconstruction,” IEEE Signal Process. Lett. 19(8), 471–474 (2012).
[Crossref]

J. Biol. Chem. (2)

P. S. Smith-Pearson, E. K. Greuber, G. Yogalingam, and A. M. Pendergast, “Abl kinases are required for invadopodia formation and chemokine-induced invasion,” J. Biol. Chem. 285(51), 40201–40211 (2010).
[Crossref] [PubMed]

H. Nagase and J. F. Woessner., “Matrix metalloproteinases,” J. Biol. Chem. 274(31), 21491–21494 (1999).
[Crossref] [PubMed]

J. Clin. Oncol. (2)

A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: biologic activity and clinical implications,” J. Clin. Oncol. 18(5), 1135–1149 (2000).
[Crossref] [PubMed]

W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O’Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen, and V. A. Levin, “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse,” J. Clin. Oncol. 17(9), 2762–2771 (1999).
[Crossref] [PubMed]

J. Natl. Cancer Inst. (1)

A. F. Chambers and L. M. Matrisian, “Changing Views of the Role of Matrix Metalloproteinases in Metastasis,” J. Natl. Cancer Inst. 89(17), 1260–1270 (1997).
[Crossref] [PubMed]

J. Neurooncol. (1)

T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70(2), 217–228 (2004).
[Crossref] [PubMed]

Med. Phys. (1)

G. Wang, Y. Li, and M. Jiang, “Uniqueness theorems in bioluminescence tomography,” Med. Phys. 31(8), 2289–2299 (2004).
[Crossref] [PubMed]

Mol. Imaging (1)

A. McCaffrey, M. A. Kay, and C. H. Contag, “Advancing molecular therapies through in vivo bioluminescent imaging,” Mol. Imaging 2(2), 75–86 (2003).
[Crossref] [PubMed]

Mol. Imaging Biol. (1)

M. Folaron and M. Seshadri, “Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas,” Mol. Imaging Biol. 18(6), 860–869 (2016).
[Crossref] [PubMed]

N. Engl. J. Med. (1)

R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med. 352(10), 987–996 (2005).
[Crossref] [PubMed]

Nat. Biotechnol. (1)

V. Ntziachristos, J. Ripoll, L. V. Wang, and R. Weissleder, “Looking and listening to light: the evolution of whole-body photonic imaging,” Nat. Biotechnol. 23(3), 313–320 (2005).
[Crossref] [PubMed]

Nat. Med. (1)

C. Bremer, C. H. Tung, and R. Weissleder, “In vivo molecular target assessment of matrix metalloproteinase inhibition,” Nat. Med. 7(6), 743–748 (2001).
[Crossref] [PubMed]

Nat. Rev. Cancer (1)

M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nat. Rev. Cancer 2(3), 161–174 (2002).
[Crossref] [PubMed]

Nature (1)

L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature 284(5751), 67–68 (1980).
[Crossref] [PubMed]

Neoplasia (1)

A. Rehemtulla, L. D. Stegman, S. J. Cardozo, S. Gupta, D. E. Hall, C. H. Contag, and B. D. Ross, “Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,” Neoplasia 2(6), 491–495 (2000).
[Crossref] [PubMed]

Oncol. Rep. (1)

H. Hu, J. Liu, L. Yao, J. Yin, N. Su, X. Liu, F. Cao, J. Liang, Y. Nie, and K. Wu, “Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model,” Oncol. Rep. 27(6), 1937–1943 (2012).
[PubMed]

PLoS One (1)

Q. Li, B. Chen, J. Cai, Y. Sun, G. Wang, Y. Li, R. Li, Y. Feng, B. Han, J. Li, Y. Tian, L. Yi, and C. Jiang, “Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma,” PLoS One 11(3), e0151815 (2016).
[Crossref] [PubMed]

Proc. Natl. Acad. Sci. U.S.A. (2)

J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses, “Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model,” Proc. Natl. Acad. Sci. U.S.A. 97(8), 3884–3889 (2000).
[Crossref] [PubMed]

J. Gross and C. M. Lapiere, “Collagenolytic activity in amphibian tissues: a tissue culture assay,” Proc. Natl. Acad. Sci. U.S.A. 48(6), 1014–1022 (1962).
[Crossref] [PubMed]

Surg. Neurol. (1)

P. K. Kornblith, W. C. Welch, and M. K. Bradley, “The future of therapy for glioblastoma,” Surg. Neurol. 39(6), 538–543 (1993).
[Crossref] [PubMed]

Other (2)

M. Brada, and M. Prados (ed). Brain Cancer,” Ann Oncol 13, 1511 (2002).

M. F. Stevens, J. A. Hickman, S. P. Langdon, D. Chubb, L. Vickers, R. Stone, G. Baig, C. Goddard, N. W. Gibson, and J. A. Slack, Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine (William B. Eerdmans, 1987), pp. 5846–5852.

Cited By

OSA participates in Crossref's Cited-By Linking service. Citing articles from OSA journals and other participating publishers are listed here.

Alert me when this article is cited.


Figures (8)

Fig. 1
Fig. 1 The schematic of the Micro-CT/BLI system and the data processing procedure.
Fig. 2
Fig. 2 The anti-glioma therapeutic effects of TMZ for the subcutaneous glioma mouse model. (a) BLI imaging of the TMZ treatment group and control group. (b) Bioluminescence light intensity, mouse body weight, tumor volume and percent survival of the TMZ treatment group and control group.
Fig. 3
Fig. 3 The evaluation of TMZ treatment effects of the orthotopic glioma mouse model using bioluminescence imaging (BLI). (a) BLI of the TMZ treatment and control groups. (b) BLI light intensity, mouse body weight and percent survival of the TMZ treatment group and control group. (c) MRI and histology staining of the mouse glioma in the TMZ treatment group and control group.
Fig. 4
Fig. 4 BLT from the control and TMZ treatment groups. The reconstructed source distribution is shown in (a, e) from three different angles, including the transverse slice (b, f), coronal slice (c, g) and sagittal slice (d, h).
Fig. 5
Fig. 5 The fluorescence expression level of MMP-750 probe on subcutaneous human U87MG glioma with TMZ treatment. (a) and (b) The tumor location via BLI. (c) and (d) The fluorescence signal of MMP-750 of the control group and the TMZ treatment group at different time points. (e) The tumor to background ratio (TBR) of FMI. (f) The ex vivo FMI imaging of the tumors and other major organs.
Fig. 6
Fig. 6 The fluorescence expression level of the MMP-750 probe on orthotopic human U87MG glioma with or without TMZ treatment. (a) and (b) The glioma location in the brain of tumor-bearing mice via BLI. (c) and (d) The fluorescence signal of MMP-750 of the control group and the TMZ treatment group at different time points. (e) The tumor to background ratio (TBR) of FMI. (f) FMI imaging of tumors and other major organs of the mice.
Fig. 7
Fig. 7 MMP2 and MMP3 at both RNA and protein levels after treatment with TMZ in in vitro experiments.
Fig. 8
Fig. 8 The immunohistology and western blot staining of MMP2 and MMP3 for mouse glioma xenografts after treatment with TMZ.

Tables (1)

Tables Icon

Algorithm 1 Adaptive Sparsity Matching Pursuit (ASMP)

Equations (1)

Equations on this page are rendered with MathJax. Learn more.

v=1/2 x y 2

Metrics